Poorva Vaidya

Title(s)Assistant Health Sciences Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
ORCID ORCID Icon0000-0002-5506-4250 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, Los AngelesB.S.06/2013Molecular, Cell and Developmental Biology
    Georgetown University School of MedicineM.D.05/2017Medicine
    Los Angeles County/University of Southern California06/2020Internal Medicine Residency
    University of California, San Diego06/2024Hematology/Oncology Fellowship

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence. Clin Cancer Res. 2024 Apr 01; 30(7):1232-1239. Vaidya P, Cohen EEW. PMID: 37955563; PMCID: PMC10984792.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine. Leuk Res Rep. 2024; 21:100408. Vaidya P, Wang HY, Don MD, Hinds BR, Mangan JK. PMID: 38269085; PMCID: PMC10805932.
      View in: PubMed   Mentions:
    3. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol. 2021 Jun; 147(6):1803-1811. In GK, Vaidya P, Filkins A, Hermel DJ, King KG, Ragab O, Tseng WW, Swanson M, Kokot N, Lang JE, Menendez L, DeClerck B, Kim G, Hu JC, Terando A, Jadvar H, Ricker C, Miller KA, Peng DH, Wysong A. PMID: 33210210.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    4. Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. JCO Clin Cancer Inform. 2020 06; 4:583-601. Hasnain Z, Nilanon T, Li M, Mejia A, Kolatkar A, Nocera L, Shahabi C, Cozzens Philips FA, Lee JSH, Hanlon SE, Vaidya P, Ueno NT, Yennu S, Newton PK, Kuhn P, Nieva J. PMID: 32598179; PMCID: PMC7328110.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    5. Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors. World J Oncol. 2019 Dec; 10(6):226-230. Hagiya A, Vaidya P, Khedro T, Yaghmour B, Siddiqi I, Yaghmour G. PMID: 31921378; PMCID: PMC6940036.
      View in: PubMed   Mentions: 1  
    6. Midostaurin-Related Interstitial Lung Injury in FLT3+ Acute Myeloid Leukemia Post-Allogeneic Transplant. World J Oncol. 2019 Dec; 10(6):237-239. Vaidya P, Khedro T, Yaghmour B, Yaghmour G. PMID: 31921380; PMCID: PMC6940037.
      View in: PubMed   Mentions: 2  
    7. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019 Sep; 5(9):763-766. Vaidya P, Mehta A, Ragab O, Lin S, In GK. PMID: 31516991; PMCID: PMC6728732.
      View in: PubMed   Mentions: 6  
    8. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med. 2014 Aug 20; 6(250):250ra114. Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RM, Vaidya P, Munoz MA, Schenk M, Swindell WR, Chun R, Zavala K, Hewison M, Adams JS, Horvath S, Pellegrini M, Bloom BR, Modlin RL. PMID: 25143364; PMCID: PMC4175914.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    Poorva's Networks
    Concepts (33)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (22)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California